Cognitive Impairment in Ageing People

Study Overview
=================
Brief Summary
-----------------
Mild cognitive impairment (MCI) and neurocognitive disorder such as Alzheimer's disease (AD) and Vascular dementia (VaD) have become common diseases in the elderly. The burden of dementia is rising in China, with major medical, social and economic impacts. To address this important public health problem, cohort study on elderly cognitive disorders should be carry out. The methods of early prevention, early diagnosis and early treatment the cognitive disorders in elderly should be found to reduce the burden of the social and economic issue due to dementia. At present, the international corresponding guidelines have taken gene and brain imaging biomarkers as important indicators of dementia pathogenesis research, accurate diagnosis and targeted intervention. The study will construct a prospective cohort to establish database that provide not only comprehensive epidemiological data on the MCI and neurocognitive disorder in ageing people, but also complete the construction of biological samples bank and clinical diagnosis and treatment information database. Using the database, the study will identify the conversion rates from MCI to dementia and risk factors for the progression from MCI to dementia or AD. The study will also apply and develop brain structural and pathological imaging technology to support precision diagnosis of senile cognitive disorders. The study have goals to identify and validate imaging and blood/CSF biomarkers for the early detection and tracking of cognitive disorders.

Official Title
-----------------
Cognitive Impairment in Ageing People: A Longitudinal Observational Prospective Study

Conditions
-----------------
MCI, Alzheimer Disease, VAD - Vascular Dementia, Cognitive Impairment

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients over 50 years old. Sign informed consent. According to DSM-IV, the diagnostic standard of dementia was not met. The clinical dementia rating (CDR) was 0.5. Exclusion criteria: Subjects with mental retardation. Refuse to have blood sampling, imaging and other examinations. Uncooperative subjects that have serious organic diseases, or have a history of mental illness, or have physical disability (including severe aphasia). Contraindications of MR scanning. Suffering from serious physical or mental illness.

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Normal Aging<br>Normal Aging with normal cognitive function | |
| Mild cognitive impairment (MCI)<br>Mild cognitive impairment subjects with memory loss as predominant symptom | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of Dementia |  | April 2020 to December 2040 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The conversion rate of normal elderly to MCI to neurocognitive disorder |  | April 2020 to December 2040 | 
| Improvement of Cognitive Function based on Montreal Cognitive Assessment (MoCA) score |  | April 2020 to December 2040 |